JAMA : the journal of the American Medical Association JAMA, 329(1), 39-51. American Medical Association Journal of the American Medical Association Journal of the American Medical Association, 2023, 329 (1), pp.39-51. ⟨10.1001/jama.2022.23257⟩ Jama : Journal of the American Medical Association, 329, 1, pp. 39-51 Higgins, A M, Berry, L R, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, P R, Al-Beidh, F, Annane, D, Arabi, Y M, Beane, A, Van Bentum-Puijk, W, Bhimani, Z, Bonten, M J M, Bradbury, C A, Brunkhorst, F M, Burrell, A, Buzgau, A, Buxton, M, Charles, W N, Cove, M, Detry, M A, Estcourt, L J, Fagbodun, E O, Fitzgerald, M, Girard, T D, Goligher, E C, Goossens, H, Haniffa, R, Hills, T, Horvat, C M, Huang, D T, Ichihara, N, Lamontagne, F, Marshall, J C, McAuley, D F, McGlothlin, A, McGuinness, S P, McVerry, B J, Neal, M D, Nichol, A D, Parke, R L, Parker, J C, Parry-Billings, K, Peters, S E C, Reyes, L F, Rowan, K M, Saito, H, Santos, M S, Saunders, C T & Serpa-Neto, A 2023, ' Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial ', JAMA, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Bradbury, C A & Higgins, A M 2023, ' Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial ', JAMA-Journal of the American Medical Association, vol. 329, no. 1, pp. 39-51 . https://doi.org/10.1001/jama.2022.23257 Jama : Journal of the American Medical Association, 329, 39-51 JAMA
Dipòsit Digital de la UB Universidad de Barcelona Rosas, I O, Bräu, N, Waters, M, Go, R C, Malhotra, A, Hunter, B D, Bhagani, S, Skiest, D, Savic, S, Douglas, I S, Garcia-Diaz, J, Aziz, M S, Cooper, N, Youngstein, T, Sorbo, L D, De La Zerda, D J, Ustianowski, A, Gracian, A C, Blyth, K G, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C H, Rohatgi, N, Wiese, L, Luyt, C E, Bauer, R N, Cai, F, Lee, I T, Matharu, B, Metcalf, L, Wildum, S, Graham, E, Tsai, L & Bao, M 2022, ' Tocilizumab in patients hospitalised with COVID-19 pneumonia : Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) ', EClinicalMedicine, vol. 47, 101409 . https://doi.org/10.1016/j.eclinm.2022.101409